Diploma PLC (LON:DPLM - Get Free Report) shares rose 15.1% during mid-day trading on Wednesday following insider buying activity. The stock traded as high as GBX 5,025 ($68.00) and last traded at GBX 4,860 ($65.76). Approximately 975,747 shares changed hands during trading, an increase of 115% from the average daily volume of 453,933 shares. The stock had previously closed at GBX 4,222 ($57.13).
Specifically, insider Katie Bickerstaffe purchased 39 shares of Diploma stock in a transaction that occurred on Tuesday, May 20th. The shares were acquired at an average cost of GBX 4,981 ($67.40) per share, for a total transaction of £1,942.59 ($2,628.67). Also, insider Katie Bickerstaffe purchased 13 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were purchased at an average price of GBX 4,982 ($67.42) per share, for a total transaction of £647.66 ($876.40).
Diploma Stock Down 0.5%
The company has a debt-to-equity ratio of 62.17, a current ratio of 2.17 and a quick ratio of 0.80. The stock's 50 day simple moving average is GBX 3,999.40 and its two-hundred day simple moving average is GBX 4,261. The firm has a market cap of £6.32 billion, a P/E ratio of 54.47, a P/E/G ratio of 2.82 and a beta of 0.75.
Diploma (LON:DPLM - Get Free Report) last issued its earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.09) earnings per share for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. As a group, research analysts forecast that Diploma PLC will post 163.7995512 earnings per share for the current year.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Further Reading
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
